TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39714090

Group type: EXPERIMENTAL
Intervention: Extended Reality (ER) program for 14 weeks including active video gaming and mindfulness practices.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care in the hospital followed by an 8-week home ER program after a waiting period.
Number of subjects: 16
Study: 39714546

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg capsules twice daily
Number of subjects: 5717
Study: 39714620

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 8854
Study: 39714637

Group type: EXPERIMENTAL
Intervention: Low-Intensity Group (LIG)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Group (MIG)
Number of subjects: 101
Study: 39714786

Group type: EXPERIMENTAL
Intervention: Independent RPM ratings of MADRS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Site ratings of MADRS
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MADRS rating pairs
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rater training and monitoring
Number of subjects: 58
Study: 39714843

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP) home visiting program
Number of subjects: 4877

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4877
Study: 39714889

Group type: EXPERIMENTAL
Intervention: Anterior gastropexy
Number of subjects: 240

Group type: COMPARATOR
Intervention: No anterior gastropexy
Number of subjects: 240
Study: 39714936

Group type: COMPARATOR
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 82

Group type: COMPARATOR
Intervention: Predictive low-glucose suspend insulin delivery
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump insulin delivery
Number of subjects: 82
Study: 39715103

Group type: EXPERIMENTAL
Intervention: Time-limited trial (TLT) initiated in the ED
Number of subjects: 40
Study: 39715234

Group type: EXPERIMENTAL
Intervention: Digital clinical decision support algorithm (CDSA) enhanced by point-of-care tests, training, and mentorship
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Digital clinical decision support algorithm (CDSA)
Number of subjects: 450
Study: 39715423

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) + mentoring
Number of subjects: 81

Group type: COMPARATOR
Intervention: Mentoring-alone
Number of subjects: 81
Study: 39715425

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Safety control condition
Number of subjects: 212
Study: 39715424

Group type: EXPERIMENTAL
Intervention: Friend-based motivational intervention (FMI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 102
Study: 39715475

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily (QD)
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study: 39715568

Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Bifidus ActiRegularis (5x10^8) strain, administered once a day for 15 consecutive days.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-pharmaceutical standard care treatment (Control).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Probiotic drink (I).
Number of subjects: 36
Study: 39715569

Group type: EXPERIMENTAL
Intervention: Motor imagery ability (assessed using Kinesthetic and Visual Imagery Questionnaire-20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mental chronometry task scores
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Motor imagery ability
Number of subjects: 60
Study: 39715573

Group type: EXPERIMENTAL
Intervention: VDOT (Video Directly Observed Therapy)
Number of subjects: 142

Group type: COMPARATOR
Intervention: UCDOT (Usual Care Directly Observed Therapy)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: VDOT
Number of subjects: 142

Group type: COMPARATOR
Intervention: UCDOT
Number of subjects: 142
Study: 39715748

Group type: EXPERIMENTAL
Intervention: Heterologous Ad26.ZEBOV/MVA-BN®-Filo prime-boost
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MVA-BN®-Filo boost at 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Homologous prime-boost
Number of subjects: 60
Study: 39715755

Group type: EXPERIMENTAL
Intervention: Toripalimab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 0
Study: 39715848

Group type: EXPERIMENTAL
Intervention: Malignant lesions
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 154
Study: 39715945

Group type: EXPERIMENTAL
Intervention: Modified ICU rooms with dynamic lighting system
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard ICU rooms
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both modified and standard ICU rooms (influence of light)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both modified and standard ICU rooms (interaction over time)
Number of subjects: 64
Study: 39716084

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) levels in the Obese + NAFLD group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) levels in the Obese group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fecal calprotectin (FC) levels in the Healthy control group
Number of subjects: 31

Group type: COMPARATOR
Intervention: FC positivity rates in the Healthy control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FC positivity rates in the Obese group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FC positivity rates in the Obese + NAFLD group
Number of subjects: 31
Study: 39716103

Group type: EXPERIMENTAL
Intervention: QuestOnco application
Number of subjects: 110

Group type: COMPARATOR
Intervention: PRO-CTCAE
Number of subjects: 110

Group type: COMPARATOR
Intervention: Medical records
Number of subjects: 110
Study: 39716127

Group type: EXPERIMENTAL
Intervention: Brief data set (EQ-5D-5L and additional generic PROMs)
Number of subjects: 2904

Group type: COMPARATOR
Intervention: Longer data set (including Patient-Specific Functional Scale and 29-item PROMIS Profile instruments)
Number of subjects: 2904
Study: 39716202

Group type: EXPERIMENTAL
Intervention: Intervention targeting emotional wellbeing and resilience
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) skills training
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Performance improvement training
Number of subjects: 400

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 400
Study: 39716203

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD) + Physical activity (PA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study: 39716323

Group type: EXPERIMENTAL
Intervention: PAL-222 (adipose tissue-derived mesenchymal stem cell sheets)
Number of subjects: 0
Study: 39716442

Group type: EXPERIMENTAL
Intervention: Acalabrutinib treatment (n=23, NP group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Acalabrutinib treatment (n=18, PD group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High surface expression of CD49d and CD79b prior to acalabrutinib therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: RNA-seq and flow cytometry profiling
Number of subjects: 41
Study: 39716523

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study: 39716659

Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 361
Study: 39716875

Group type: EXPERIMENTAL
Intervention: TAK-754 gene therapy
Number of subjects: 4
Study: 39716881

Group type: EXPERIMENTAL
Intervention: Cs-131 prostate brachytherapy (PB)
Number of subjects: 138
Study: 39716986

Group type: EXPERIMENTAL
Intervention: eLym™ System
Number of subjects: 50
Study: 39717077

Group type: EXPERIMENTAL
Intervention: Acti-Pair programme (motivational support from a peer, construction of a personalised project, support from health and adapted PA professionals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (advice and recommendations for PA during consultations)
Number of subjects: 0
Study: 39717073

Group type: EXPERIMENTAL
Intervention: Yoga intervention delivered by videoconference, 2 classes/week for 12 weeks
Number of subjects: 0
Study: 39717227

Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Time-based delayed cord clamping (TBCC)
Number of subjects: 669
Study: 39717281

Group type: EXPERIMENTAL
Intervention: Derived DVT score with 2 objective variables
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Derived DVT score with D-dimer cutoff of <0.5 µg/mL
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Wells score
Number of subjects: 1312
Study: 39717452

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 50
Study: 39717499

Group type: EXPERIMENTAL
Intervention: AHA HeartSaver® course
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: JIT training video
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 221
Study: 39717511

Group type: EXPERIMENTAL
Intervention: Intravaginal medical device
Number of subjects: 27
Study: 39717517

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy (daily administration, escalated to maximum tolerated dose over 36 months)
Number of subjects: 270
Study: 39717518

Group type: EXPERIMENTAL
Intervention: Dementia end-of-life care planning intervention with adaptations based on community engagement via a Community Advisory Board (CAB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Framework for Reporting Adaptations and Modifications to Evidence-based Interventions (FRAME) model
Number of subjects: 0
Study: 39717667

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa with chemotherapy (first-line treatment in cohorts A, B, C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa with chemotherapy (second-line treatment in cohort D)
Number of subjects: 0
Study: 39717698

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS), 80% motor threshold; 5 sessions per day; 5 days; 3 targets; 18,000 pulses/day over 2 weeks
Number of subjects: 10
Study: 39717737

Group type: EXPERIMENTAL
Intervention: Higher percentage of plasmatic palmitic acid (16:0) in cases with liver fibrosis
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (HIV mono-infected individuals without liver fibrosis)
Number of subjects: 142
Study: 39717777

Group type: COMPARATOR
Intervention: SM17 (2, 20, 70, 200, 400, 600, 1200 mg)
Number of subjects: 77

Group type: COMPARATOR
Intervention: SM17 (200, 400, 600 mg) every two weeks (Q2W) for a total of 3 doses
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SM17 (up to 1200 mg)
Number of subjects: 77
Study: 39717874

Group type: EXPERIMENTAL
Intervention: Hair cortisol concentrations (HCC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Immunological markers (T cell concentration, CD4/CD8 cell ratio, proinflammatory cytokines TNF-α, IL-6, IL-18)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 196
Study: 39717993

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8, 1.2 or 0.6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39718172

Group type: EXPERIMENTAL
Intervention: Weekly dihydroartemisinin-piperaquine (approximately 2.5 mg per kg bodyweight dihydroartemisinin and 20 mg per kg bodyweight per day piperaquine)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine (approximately 25 mg per kg bodyweight sulfadoxine and 1.25 mg per kg bodyweight)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Weekly dihydroartemisinin-piperaquine
Number of subjects: 724

Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine
Number of subjects: 724
Study: 39718497

Group type: EXPERIMENTAL
Intervention: nacVI-RADS 3 or higher
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: nacVI-RADS
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: VI-RADS 3 or higher
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: nacVI-RADS scores
Number of subjects: 110
Study: 39718599

Group type: EXPERIMENTAL
Intervention: Egg-protein hydrolysate (NWT-03) 5.7 g
Number of subjects: 44

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 44
Study: 39718747

Group type: EXPERIMENTAL
Intervention: belantamab mafodotin (2.5 mg/kg on Day 1 of each 21-day cycle) plus bortezomib and dexamethasone (Arm A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: belantamab mafodotin (2.5 mg/kg on Day 1 of the first 28-day cycle; 1.9 mg/kg on Day 1 of subsequent cycles) plus pomalidomide and dexamethasone (Arm B)
Number of subjects: 7
Study: 39718983

Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional prophylactic cranial irradiation (PCI)
Number of subjects: 106
Study: 39718991

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 39719131

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 52
Study: 39719248

Group type: EXPERIMENTAL
Intervention: Empowerment intervention (phone-based, 3 weekly sessions)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Education intervention (phone-based, 3 weekly sessions)
Number of subjects: 400
Study: 39719276

Group type: EXPERIMENTAL
Intervention: CEOAS index for assessing tooth wear (scores 0-3) and occurrence of enamel defects (scores I-III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical examinations using the CEOAS index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire addressing general health, sleep quality, dietary habits, oral hygiene habits, and parafunctional habits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of vertical dimension of occlusion (VDO)
Number of subjects: 0
Study: 39719282

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM) intervention including immediate feedback on glucose and blood pressure readings, educational videos on exercise and nutrition, and personalised support with TM nurse for 6 months.
Number of subjects: 21
Study: 39719288

Group type: EXPERIMENTAL
Intervention: Immediate free near-vision glasses and half-day training for smartphone and banking app use
Number of subjects: 484

Group type: COMPARATOR
Intervention: Glasses and training 12 months later (control)
Number of subjects: 484
Study: 39719323

Group type: EXPERIMENTAL
Intervention: Novel ERG devices (RETEval full-field and UTAS multifocal ERG)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard screening tests (spectral-domain optical coherence tomography and autofluorescence)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Novel ERG devices
Number of subjects: 140
Study: 39719417

Group type: EXPERIMENTAL
Intervention: Myectomy
Number of subjects: 173
Study: 39719423

Group type: EXPERIMENTAL
Intervention: AccuFFRangio
Number of subjects: 304

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 304
Study: 39719429

Group type: EXPERIMENTAL
Intervention: (R)-1,3-butanediol (BD) 0.5 g/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 39719465

Group type: EXPERIMENTAL
Intervention: Text-Based Adherence Game (TAG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC)
Number of subjects: 60
Study: 39719488

Group type: EXPERIMENTAL
Intervention: Elinzanetant 120 mg single dose
Number of subjects: 6
Study: 39719502

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) 2 mg
Number of subjects: 496
Study: 39719545

Group type: EXPERIMENTAL
Intervention: RENEW intervention using the digital gamification platform Kahoot! administered across eight weekly sessions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 45
Study: 39719625

Group type: EXPERIMENTAL
Intervention: LHS intervention during treatment phase
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: LHS intervention during maintenance phase
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 307
Study: 39719648

Group type: EXPERIMENTAL
Intervention: Reframe-IT+ intervention group (n=48)
Number of subjects: 1546
Study: 39719927

Group type: EXPERIMENTAL
Intervention: PRRBCs
Number of subjects: 321

Group type: COMPARATOR
Intervention: Conventional RBCs
Number of subjects: 321
Study: 39719976

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the medial pulvinar nucleus (PuM)
Number of subjects: 6
Study: 39720009

Group type: EXPERIMENTAL
Intervention: Traditional Post-Approval Study (PAS)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Real-World Data (RWD)
Number of subjects: 1015
Study: 39720422

Group type: EXPERIMENTAL
Intervention: PTSD-PRS (Polygenic Risk Score for PTSD)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: MDD-PRS (Polygenic Risk Score for Major Depressive Disorder)
Number of subjects: 1869
Study: 39720440

Group type: EXPERIMENTAL
Intervention: Estimated IQ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Executive functions
Number of subjects: 0
Study: 39720510

Group type: EXPERIMENTAL
Intervention: CNP-106 (COUR nanoparticle)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 39720677

Group type: EXPERIMENTAL
Intervention: Biomarkers (GFAP, NFL, S100B)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Existing clinical prognostic model
Number of subjects: 1025
Study: 39720838

Group type: EXPERIMENTAL
Intervention: LYB001
Number of subjects: 1200

Group type: COMPARATOR
Intervention: ZF2001
Number of subjects: 1200
Study: 39721059

Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthoses (DEFOs) applied to the lower trunk and pelvis in addition to physiotherapy and rehabilitation sessions.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional physiotherapy and rehabilitation program without DEFOs.
Number of subjects: 22
Study: 39721062

Group type: EXPERIMENTAL
Intervention: Glittre activities of daily living (ADL) test
Number of subjects: 66
Study: 39721066

Group type: EXPERIMENTAL
Intervention: Dynamic Orthosis (DO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Toe Separator (TS)
Number of subjects: 30
Study: 39721752

Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 119
Study: 39721764

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 1-hour preblock
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at the time of the block
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 1 hour postblock
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously administered at 2 hours postblock
Number of subjects: 158

Group type: COMPARATOR
Intervention: Normal saline infusions (placebo)
Number of subjects: 158
Study: 39721851

Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg as a single agent, starting with a single dose for 7 days and continuous daily dosing for 21 days, followed by 7 days off schedule)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg)
Number of subjects: 14
Study: 39722048

Group type: EXPERIMENTAL
Intervention: Intramuscular injection with electroporation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Needle-free injection system (NFIS)
Number of subjects: 0
Study: 39722269

Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Staged complete revascularization
Number of subjects: 1525
Study: 39722321

Group type: EXPERIMENTAL
Intervention: Reduced-toxicity transplant strategy with fludarabine/prednisone, treosulfan, reduced cyclophosphamide, and abatacept/sirolimus/ATG
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reduced-toxicity transplant strategy
Number of subjects: 12
Study: 39722333

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (sham-controlled trial)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Control group (sham)
Number of subjects: 493
Study: 39722400

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg every 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (switched to tildrakizumab 100 mg at W16)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 39722558

Group type: EXPERIMENTAL
Intervention: TK-OS ML models
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Random survival forest using TK4
Number of subjects: 526

Group type: COMPARATOR
Intervention: Cox model
Number of subjects: 526
Study: 39722560

Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine (two doses six months apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenACWY-CRM vaccine (one dose)
Number of subjects: 0
Study: 39722592

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Patients with AF and non-LBBB morphology
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Overall mortality between subgroups
Number of subjects: 2035
Study: 39722695

Group type: EXPERIMENTAL
Intervention: High-dose testosterone replacement therapy (TRT) with finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39723536

Group type: EXPERIMENTAL
Intervention: Compound 21 infusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy pregnancy)
Number of subjects: 24
Study: 39723608

Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2 g every other week for eight applications.
Number of subjects: 12
Study: 39723627

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + tucatinib + trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care treatment (chemotherapy combination)
Number of subjects: 0
Study: 39723995

Group type: EXPERIMENTAL
Intervention: Remotely Delivered Pelvic Yoga Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39724015

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound with microbubbles (LIPU/MB)
Number of subjects: 0